title: Energy expenditure during synthetic surfactant replacement therapy for neonatal respiratory distress syndrome.
abstract: Little information is available on the energy expenditure of infants with increased work of breathing from respiratory distress syndrome (RDS). A study was carried out to determine whether surfactant replacement therapy modifies respiratory gas exchange in newborn infants with RDS and an arterial-alveolar oxygen tension ratio of less than 0.22. In a double-blind, placebo-controlled, rescue trial, infants received either two 5 ml/kg doses of a synthetic surfactant, Exosurf Neonatal, or air placebo. Of 23 infants ventilated for RDS, 11 were randomly assigned to receive air and 12 to receive surfactant. Oxygen consumption, carbon dioxide production, respiratory quotient, and metabolic rate were measured by computerized, closed-circuit, indirect calorimetry. Concomitantly, transcutaneous oxygen and carbon dioxide tension were continuously recorded. Oxygen consumption and carbon dioxide production remained constant during the period infants received surfactant. In patients randomly assigned to surfactant, a decrease in respiratory quotient was observed after the first (p less than 0.025) but not the second dose. This decrease was possibly related to a change in substrate utilization. The improved clinical outcomes reported among infants receiving surfactant were not accompanied by changes in energy expenditure.
authors.affiliation: Perinatal Service, Hospital Sainte-Justine, Montreal, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Hazan
authors.forename: P
authors.initials: P
authors.lastname: Chessex
authors.forename: B
authors.initials: B
authors.lastname: Piedboeuf
authors.forename: M
authors.initials: M
authors.lastname: Bourgeois
authors.forename: H
authors.initials: H
authors.lastname: Bard
authors.forename: W
authors.initials: W
authors.lastname: Long
mesh_terms: D002153:Calorimetry, Indirect; D004338:Drug Combinations; D004734:Energy Metabolism / Q000187:drug effects*; D005233:Fatty Alcohols / Q000627:therapeutic use*; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D004338:Drug Combinations; D005233:Fatty Alcohols; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D011092:Polyethylene Glycols; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination